BioTuesdays

Category - Markets

MoonLake Logo
Markets

Cantor starts MoonLake at OW; PT $23

Cantor Fitzgerald initiated coverage of MoonLake Immunotherapeutics (NASDAQ:MLTX) with an “overweight” rating and a 12-month price target of $23. The stock closed at $16.30 on Feb. 13. MoonLake has an IL-17A and IL-17F...

February 14, 2023
OmniAb Logo
Markets

HCW starts OmniAb at buy; PT $11

H.C. Wainwright launched coverage of OmniAb (NASDAQ:OABI) with a “buy” rating and a price target of $11. The stock closed at $3.88 on Feb. 10. At its core, OmniAb is an antibody discovery, optimization, and licensing...

February 13, 2023
Outlook Therapeutics Logo
Markets

Cantor starts Outlook Therapeutics at OW; PT $4

Cantor Fitzgerald launched coverage of Outlook Therapeutics (NASDAQ:OTLK) with an “overweight” rating and a 12-month price target of $4. The stock closed at $1.15 on Feb. 3. Outlook is a biopharmaceutical company that...

February 6, 2023
Hepion Logo
Markets

AGP starts Hepion at buy; PT $4

Alliance Global Partners launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and price target of $4. Shares of Hepion closed at 73 cents on Jan. 31. Analyst James Molloy writes that his...

February 1, 2023
Editas-Logo
Markets

Cantor starts Editas Medicine at OW; PT $15

Cantor Fitzgerald initiated coverage of Editas Medicine (NASDAQ:EDIT) with an “overweight” rating and 12-month price target of $15. The stock closed at $9.35 on Jan. 31. Editas is a clinical-stage gene editing company...

February 1, 2023
Precigen-Logo
Markets

Cantor ups Precigen PT after R&D event

Cantor Fitzgerald raised its price target for Precigen (NASDAQ:PGEN) to $10 from $7 after the company held an R&D event to showcase safety and efficacy data from a Phase 1 trial. The stock closed at $1.64 on Jan. 27...

January 30, 2023
Celularity-Logo
Markets

HCW slashes Celularity PT on pipeline priority changes

H.C. Wainwright reduced its price target for Celularity (NASDAQ:CELU) to $2.50 from $15, but reiterated a “buy” rating, after the company unveiled a strategic shift in its pipeline. The stock closed at $1.05 on Jan. 27...

January 30, 2023
Markets

Dawson James starts Genprex at buy; PT $3

Dawson James Securities initiated coverage of Genprex (NASDAQ:GNPX) with a “buy” rating and $3 price target. The stock closed at $1.34 on Jan. 27. Genprex is a clinical-stage gene therapy company pioneering the...

January 30, 2023
Compass-Logo
Markets

Stifel starts Compass Therapeutics at buy; PT $9

Stifel initiated coverage of Compass Therapeutics (NASDAQ:CMPX) with a “buy” rating and price target of $9. The stock closed at $3.95 on Jan. 26. “We believe the recent presentation at ASCO-GI 2023 of updated results...

January 27, 2023